Literature DB >> 30073908

Immune-mediated encephalitis with daclizumab: The final nail.

Thomas Williams1, Jeremy Chataway1.   

Abstract

We provide clinical commentary on this edition's case report of immune-mediated encephalitis related to daclizumab therapy.

Entities:  

Keywords:  Daclizumab; encephalitis; multiple sclerosis

Mesh：

Substances：

Year:  2018        PMID： 30073908     DOI： 10.1177/1352458518791374

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  3 in total

1.  Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells.

Authors:  Namita A Goyal; Gérald Coulis; Jorge Duarte; Philip K Farahat; Ali H Mannaa; Jonathan Cauchii; Tyler Irani; Nadia Araujo; Leo Wang; Marie Wencel; Vivian Li; Lishi Zhang; Steven A Greenberg; Tahseen Mozaffar; S Armando Villalta
Journal:  Neurology       Date:  2022-02-07       Impact factor: 9.910

Review 2.  What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?

Authors:  Julia Krämer; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2022-07-06       Impact factor: 6.088

Review 3.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.